The Delaware Congressional Delegation announced a $10 million grant to the University of Delaware’s National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
The funding will support the construction of a Good Manufacturing Practices (cGMP) facility known as the SABRE Center (Securing American Bio-Manufacturing Research and Education). The facility will be located north of NIIMBL’s current location on the University of Delaware’s STAR Campus. It will support NIIMBL’s work in biopharmaceutical innovation, allowing for space for the clinical research and production of biopharmaceutical products to address future public health threats.
“Investing in NIIMBL means investing in the health of our families, the competitiveness of our economy, and the growth of Delaware as a hub for biotechnology and biomanufacturing,” said U.S Sen. Chris Coons. “I am thrilled to have secured $10 million in additional Congressionally Directed Spending to support biopharmaceutical innovation and help ensure our state remains a global leader in research and innovation while creating good-paying jobs and helping address future public health challenges.”
“This funding will help build new capabilities that will accelerate and enhance our country’s ability to stay at the leading edge of biopharmaceutical manufacturing innovation and ensure we have a world-leading biomanufacturing workforce,” said Kelvin Lee, institute director for NIIMBL.
